Literature DB >> 11096607

Localized Hepatocellular Carcinoma.

.   

Abstract

Hepatocellular carcinoma (HCC) most commonly affects patients with underlying cirrhosis. Screening of cirrhotic patients can result in early detection of HCC. If the tumor is localized to the liver, the patient can be offered therapy. It is our belief that those patients with good liver function (Child-Pugh A/B or better) should be considered for surgical resection of one or two surgical segments of the liver. Otherwise, ablative measures, including radiofrequency ablation (RFA), cryotherapy, or angiographic embolization should be offered to the patient. Alternatively, direct injection of alcohol or acetic acid can result in effective ablation of the lesion, with unclear effects on long-term outcome. Chemotherapy does not appear to impact survival, but it is our belief that combined protocols may offer superior outcomes to single therapeutic interventions. Orthotopic liver transplantation (OLT) can have excellent efficacy in a very select group of patients.

Entities:  

Year:  2000        PMID: 11096607     DOI: 10.1007/s11938-000-0035-6

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  34 in total

1.  Percutaneous hot saline injection therapy: effectiveness in large hepatocellular carcinoma.

Authors:  H K Yoon; H Y Song; K B Sung; Y H Chung; Y S Lee; D J Suh; S G Lee; Y H Auh
Journal:  J Vasc Interv Radiol       Date:  1999-04       Impact factor: 3.464

2.  Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy.

Authors:  H Lau; K Man; S T Fan; W C Yu; C M Lo; J Wong
Journal:  Br J Surg       Date:  1997-09       Impact factor: 6.939

3.  Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.

Authors:  W Y Lau; T W Leung; S K Ho; M Chan; D Machin; J Lau; A T Chan; W Yeo; T S Mok; S C Yu; N W Leung; P J Johnson
Journal:  Lancet       Date:  1999-03-06       Impact factor: 79.321

4.  Hepatocellular carcinoma.

Authors:  A M Di Bisceglie; R L Carithers; G J Gores
Journal:  Hepatology       Date:  1998-10       Impact factor: 17.425

5.  5-Fluorouracil plus high dose levofolinic acid and oral hydroxyurea for the treatment of primary hepatocellular carcinomas: results of a phase II multicenter study of the Southern Italy Oncology Group (G.O.I.M.).

Authors:  V Gebbia; E Maiello; G Serravezza; F Giotta; A Testa; N Borsellino; G Pezzella; G Colucci
Journal:  Anticancer Res       Date:  1999 Mar-Apr       Impact factor: 2.480

6.  Initial experience with laparoscopic ultrasound-guided radiofrequency thermal ablation of hepatic tumours.

Authors:  A Cuschieri; J Bracken; L Boni
Journal:  Endoscopy       Date:  1999-05       Impact factor: 10.093

7.  Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant.

Authors:  D R Jeyarajah; T A Gonwa; M McBride; G Testa; O Abbasoglu; B S Husberg; M F Levy; R M Goldstein; G B Klintmalm
Journal:  Transplantation       Date:  1997-12-27       Impact factor: 4.939

8.  Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients.

Authors:  S Markovic; E Gadzijev; B Stabuc; L S Croce; F Masutti; M Surlan; P Berden; E Brencic; A Visnar-Perovic; F Sasso; V Ferlan-Marolt; F P Mucelli; R Cesar; M Sponza; C Tiribelli
Journal:  J Hepatol       Date:  1998-10       Impact factor: 25.083

9.  Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC.

Authors:  G Pelletier; M Ducreux; F Gay; M Luboinski; H Hagège; T Dao; W Van Steenbergen; C Buffet; P Rougier; M Adler; J P Pignon; A Roche
Journal:  J Hepatol       Date:  1998-07       Impact factor: 25.083

Review 10.  Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation.

Authors:  E Mor; R Tur-Kaspa; P Sheiner; M Schwartz
Journal:  Ann Intern Med       Date:  1998-10-15       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.